2 1 Shi Ji Jing Ji Bao Dao·2025-07-17 06:27Group 1 - The innovative drug sector in A-shares and Hong Kong stocks has seen significant gains, with the Tianhong Innovative Drug ETF (517380) rising by 3.63% and many constituent stocks, such as Sangfor and Kexing, increasing by over 10% [1] - The Tianhong Innovative Drug ETF (517380) is the largest in the market, covering both A-shares and Hong Kong stocks, and tracks the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index, which has a cumulative weight of nearly 60% in its top ten constituent stocks [1] - The Biopharmaceutical ETF (159859) also experienced a rise of 1.28%, with a trading volume exceeding 95 million yuan, and notable gains in constituent stocks like Shenzhou Cell and Anke Bio [1][2] Group 2 - The biopharmaceutical ETF (159859) closely tracks the National Securities Biopharmaceutical Index and is currently the largest in its category [2] - A cooperation agreement was signed between the Hunan Provincial Government and the National Administration of Traditional Chinese Medicine to build a national Chinese medicinal material germplasm resource bank, which aims to enhance the sustainable development of traditional Chinese medicine resources [2] - The innovative drug sector remains a key investment focus, driven by improved biotech financing and supportive domestic policies, alongside the positive earnings forecast from WuXi AppTec [2][3] Group 3 - The innovative drug sector's sustainability is supported by ongoing policy backing, enhanced global competitiveness, and the realization of commercial profits [3] - There is a focus on the improving fundamentals of the innovative drug industry chain, with recovery trends observed in overseas orders and domestic business autonomy [3]